Endometrial Intraepithelial Neoplasia

Obstetrics and Gynecology

Volumn 125, Issue 5, 2015, Pages 1272-1278

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

GESTAGEN;

BLEEDING; CANCER DIAGNOSIS; CLINICAL ASSESSMENT; CONSERVATIVE TREATMENT; DIAGNOSTIC IMAGING; DISEASE CLASSIFICATION; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; HORMONAL THERAPY; HUMAN; INTRAEPITHELIAL NEOPLASIA; POSTMENOPAUSE; PRECANCER; PRIORITY JOURNAL; REVIEW; TOTAL HYSTERECTOMY; ADENOCARCINOMA IN SITU; CARCINOMA IN SITU; CURETTAGE; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; FROZEN SECTION; HYPERPLASIA; HYSTEROSCOPY; PATHOLOGY; PRECANCEROUS CONDITIONS;

ADENOCARCINOMA IN SITU; CARCINOMA IN SITU; DILATATION AND CURETTAGE; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; FROZEN SECTIONS; HUMANS; HYPERPLASIA; HYSTEROSCOPY; PRECANCEROUS CONDITIONS;

EID: 84937551583     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/01.AOG.0000465189.50026.20     Document Type: Review

References (36)

1. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000;13:295–308. [PubMed] [Full Text]
2. Silverberg SG, Kurman RJ, Nogales F, Mutter GL, Kubik-Huch RA, Tavassoli FA. Epithelial tumours and related lesions. In: Tavassoli FA, Devilee P, editors. Pathology and genetics of tumours of the breast and female genital organs. World Health Organization classification of tumours. Lyon (France): IARC Press; 2003. p. 221–32.
3. Kendall BS, Ronnett BM, Isacson C, Cho KR, Hedrick L, Diener-West M, et al. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. Am J Surg Pathol 1998;22: 1012–9. [PubMed]
4. Zaino RJ, Kauderer J, Trimble CL, Silverberg SG, Curtin JP, Lim PC, et al. Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006;106:804–11. [PubMed] [Full Text]
5. Mutter GL, Baak JP, Crum CP, Richart RM, Ferenczy A, Faquin WC. Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. J Pathol 2000;190:462–9. [PubMed]
6. Mutter GL. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. Gynecol Oncol 2000;76:287–90. [PubMed]
7. Baak JP, Mutter GL, Robboy S, van Diest PJ, Uyterlinde AM, Orbo A, et al. The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. Cancer 2005;103: 2304–12. [PubMed] [Full Text]
8. Mutter GL, Kauderer J, Baak JP, Alberts D. Biopsy histomorphometry predicts uterine myoinvasion by endometrial carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology Group. Hum Pathol 2008;39: 866–74. [PubMed] [Full Text]
9. Hecht JL, Ince TA, Baak JP, Baker HE, Ogden MW, Mutter GL. Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis. Mod Pathol 2005;18:324–30. [PubMed] [Full Text]
10. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ 2nd, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006;106:812–9. [PubMed] [Full Text]
11. Stock RJ, Kanbour A. Prehysterectomy curettage. Obstet Gynecol 1975;45:537–41. [PubMed] [Obstetrics & Gynecology]
12. Ben-Baruch G, Seidman DS, Schiff E, Moran O, Menczer J. Outpatient endometrial sampling with the Pipelle curette. Gynecol Obstet Invest 1994;37:260–2. [PubMed]
13. Leitao MM Jr, Han G, Lee LX, Abu-Rustum NR, Brown CL, Chi DS, et al. Complex atypical hyperplasia of the uterus: characteristics and prediction of underlying carcinoma risk. Am J Obstet Gynecol 2010;203:349.e1–349.e6. [PubMed] [Full Text]
14. Bedner R, Rzepka-Gorska I. Hysteroscopy with directed biopsy versus dilatation and curettage for the diagnosis of endometrial hyperplasia and cancer in perimenopausal women. Eur J Gynaecol Oncol 2007;28:400–2. [PubMed]
15. Allison KH, Reed SD, Voigt LF, Jordan CD, Newton KM, Garcia RL. Diagnosing endometrial hyperplasia: why is it so difficult to agree? Am J Surg Pathol 2008;32:691–8. [PubMed] [Full Text]
16. The role of transvaginal ultrasonography in the evaluation of postmenopausal bleeding. ACOG Committee Opinion No. 440. American College of Obstetricians and Gynecologists. Obstet Gynecol 2009;114:409–11. [PubMed] [Obstetrics & Gynecology]
17. Supracervical hysterectomy. ACOG Committee Opinion No. 388. American College of Obstetricians and Gynecologists. Obstet Gynecol 2007;110:1215–7. [PubMed] [Obstetrics & Gynecology]
18. Stephan JM, Hansen J, Samuelson M, McDonald M, Chin Y, Bender D, et al. Intra-operative frozen section results reliably predict final pathology in endometrial cancer. Gynecol Oncol 2014;133:499–505. [PubMed] [Full Text]
19. Morotti M, Menada MV, Moioli M, Sala P, Maffeo I, Abete L, et al. Frozen section pathology at time of hysterectomy accurately predicts endometrial cancer in patients with preoperative diagnosis of atypical endometrial hyperplasia. Gynecol Oncol 2012;125:536–40. [PubMed] [Full Text]
20. AlHilli MM, Podratz KC, Dowdy SC, Bakkum-Gamez JN, Weaver AL, McGree ME, et al. Preoperative biopsy and intraoperative tumor diameter predict lymph node dissemination in endometrial cancer. Gynecol Oncol 2013; 128:294–9. [PubMed] [Full Text]
21. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014 [published erratum appears in CA Cancer J Clin 2014;64:364]. CA Cancer J Clin 2014;64:9–29. [PubMed]
22. Kim JJ, Chapman-Davis E. Role of progesterone in endometrial cancer. Semin Reprod Med 2010;28:81–90. [PubMed]
23. Perino A, Quartararo P, Catinella E, Genova G, Cittadini E. Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices. Acta Eur Fertil 1987;18: 137–40. [PubMed]
24. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997;90:434–40. [PubMed] [Obstetrics & Gynecology]
25. Vereide AB, Kaino T, Sager G, Arnes M, Orbo A. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. Gynecol Oncol 2006;101:214–23. [PubMed] [Full Text]
26. Wheeler DT, Bristow RE, Kurman RJ. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol 2007;31:988–98. [PubMed]
27. Wildemeersch D, Janssens D, Pylyser K, De Wever N, Verbeeck G, Dhont M, et al. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up. Maturitas 2007;57:210–3. [PubMed] [Full Text]
28. Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ, et al. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia-a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol 2008;139:169–75. [PubMed] [Full Text]
29. Orbo A, Arnes M, Hancke C, Vereide AB, Pettersen I, Larsen K. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol Oncol 2008;111:68–73. [PubMed] [Full Text]
30. Lee SY, Kim MK, Park H, Yoon BS, Seong SJ, Kang JH, et al. The effectiveness of levonorgestrel releasing intrauterine system in the treatment of endometrial hyperplasia in Korean women. J Gynecol Oncol 2010;21:102–5. [PubMed] [Full Text]
31. Wang S, Pudney J, Song J, Mor G, Schwartz PE, Zheng W. Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia-precursor of endometrial cancer. Gynecol Oncol 2003;88:108–17. [PubMed] [Full Text]
32. Affinito P, Di Carlo C, Di Mauro P, Napolitano V, Nappi C. Endometrial hyperplasia: efficacy of a new treatment with a vaginal cream containing natural micronized progesterone. Maturitas 1994;20:191–8. [PubMed]
33. Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 1989;160:126–31. [PubMed] [Full Text]
34. Gal D, Edman CD, Vellios F, Forney JP. Long-term effect of megestrol acetate in the treatment of endometrial hyperplasia. Am J Obstet Gynecol 1983;146:316–22. [PubMed]
35. Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2010;203:547.e1–547.10. [PubMed] [Full Text]
36. Gien L, Kwon J, Oliver TK, Fung-Kee-Fung M. Adjuvant hormonal therapy for stage I endometrial cancer. Curr Oncol 2008;15:126–35. [PubMed] [Full Text]